Phase I study of DMOT4039A, an antibody-drug conjugate targeting mesothelin, in patients with unresectable pancreatic or platinum-resistant ovarian cancer

Colin D. Weekes, Laetitia E. Lamberts, Mitesh J. Borad, Johannes Voortman, Robert R. McWilliams, Jennifer R. Diamond, Elisabeth G.E. De Vries, Henk M. Verheul, Christopher H. Lieu, George P. Kim, Yulei Wang, Suzie J. Scales, Divya Samineni, Flavia Brunstein, Younjeong Choi, Daniel J. Maslyar, Gerardo Colon-Otero

Research output: Contribution to journal › Article › peer-review

49 Scopus citations

Fingerprint

Dive into the research topics of 'Phase I study of DMOT4039A, an antibody-drug conjugate targeting mesothelin, in patients with unresectable pancreatic or platinum-resistant ovarian cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences